Disease on EC 1.14.14.55 - quinine 3-monooxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type xenobiotic transporter deficiency
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism.
Abscess
Erratum: A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19 patient.
Achlorhydria
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Acne Vulgaris
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Acute Coronary Syndrome
A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes.
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update.
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome.
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.
Genetic and nongenetic factors influencing the response to clopidogrel.
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Genetic variability in response to clopidogrel therapy and its clinical implications.
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome.
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.
Pharmacokinetics and Pharmacodynamics Following Maintenance Doses of Prasugrel and Clopidogrel in Chinese Carriers of CYP2C19 Variants.
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Resistance to clopidogrel: a review of the evidence.
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation.
The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome.
[Correlation between CYP2C19 Gene Polymorphism with Clopidogrel Resistance and Distribution of Chinese Medicine Syndrome in 229 Acute Coronary Syndrome Patients].
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
[THE FIRST RESULTS OF THE PREVALENCE OF CYP2C19 GENEPOLYMORPHISM IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE AKTYUBINSK POPULATION].
Acute Kidney Injury
Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.
Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure.
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Addison Disease
Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction.
Adenocarcinoma
3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease.
Cytochrome P450 expression (CYP) in non-small cell lung cancer.
Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance.
Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid.
Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1?,25-dihydroxyvitamin D? function in human colon adenocarcinoma LS180 cells.
Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.
Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.
Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.
Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas.
Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway.
[Regulatory mechanisms of gut microbiota on intestinal CYP3A and P-glycoprotein in rats with dextran sulfate sodium-induced colitis].
Adenocarcinoma of Lung
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.
The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.
Adenoma
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma.
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Adrenal Cortex Neoplasms
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5?-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Adrenal Hyperplasia, Congenital
Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.
Adrenal Insufficiency
Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
Rapid Onset of Iatrogenic Adrenal Insufficiency in a Patient with Cystic Fibrosis-Related Liver Disease Treated with Inhaled Corticosteroids and a Moderate CYP3A4 Inhibitor.
Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone.
Adrenocortical Carcinoma
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Alopecia
Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Altitude Sickness
[Effect of high altitude hypoxia on the activity and protein expression of CYP2C9 and CYP2C19].
Alzheimer Disease
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole.
Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: An insight into the efflux-metabolism alliance.
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Amyotrophic Lateral Sclerosis
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Anemia, Aplastic
Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients.
Anemia, Hemolytic
Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Anemia, Sickle Cell
(281) Genetic variability of UGT2B7, CYP3A4, CYP3A5 and CYP2B6 DMETs in a sickle cell disease patient cohort.
Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.
Angina, Stable
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina.
Intravenous diltiazem and CYP3A-mediated metabolism.
Angina, Unstable
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year old man.
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Apnea
Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula.
Argininosuccinic Aciduria
Regulation of CYP1A and CYP3A mRNAs by ascorbic acid in guinea pigs.
Arrhythmias, Cardiac
Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Cisapride and ventricular arrhythmia.
Drugs and cardiotoxicity in HIV and AIDS.
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
[Drug-food interactions]
Arthritis
Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats.
Arthritis, Experimental
Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Arthritis, Psoriatic
Allelic variants of drug metabolizing enzymes as risk factors in psoriasis.
Arthritis, Rheumatoid
4?-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis.
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Discovery of novel PI3-kinase ? specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis.
Aspergillosis
A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms.
Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.
Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Asthma
Association of matrix metalloproteinase 8 genetic polymorphisms with bronchial asthma in a Japanese population.
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
CYP2C19 gene polymorphism may be a risk factor for bronchial asthma.
Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.
Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control.
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.
Ataxia
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Atherosclerosis
Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.
Atrial Fibrillation
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI.
Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?
Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model.
[Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].
Azoospermia
Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia.
Barrett Esophagus
Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.
beta-Thalassemia
Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.
Bile Reflux
Rapid progressive long esophageal stricture caused by gastroesophageal reflux disease after pylorus-preserving pancreatoduodenectomy.
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
Biliary Tract Neoplasms
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
Blister
Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes.
Brain Death
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Brain Diseases
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Brain Neoplasms
P450-expression in brain tumors.
Breast Neoplasms
A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma.
African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.
Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies.
Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis.
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
Association of CYP2C19*2 and Associated Haplotypes with Lower Norendoxifen Levels in Tamoxifen-treated Asian Breast Cancer Patients.
Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women.
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen.
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Clinical drug interaction profile of idelalisib in healthy subjects.
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.
Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
CYP2C and IL-6 expression in breast cancer.
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
CYP2C19*17 is associated with decreased breast cancer risk.
CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.
CYP3A variation, premenopausal estrone levels, and breast cancer risk.
CYP3A4 expression in breast cancer and its association with risk factors in Mexican women.
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
CYP3A4 mediates growth of ER+ breast cancer cells, in part, by nuclear translocation of phospho-Stat3 through biosynthesis of ({+/-})-14,15-EET.
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.
Epidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer risk.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer.
Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.
Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism.
Multi-gene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19 and ABCB1.
NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Novel mutations of CYP3A4 in fine needle aspiration cytology samples of breast cancer patients and its clinical correlations.
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.
Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women.
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.
Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer.
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNF? biologic for ulcerative colitis: a case report.
PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.
PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Reductive amination-assisted quantitation of tamoxifen and its metabolites by liquid phase chromatography tandem mass spectrometry.
Regioselective hydroxylation of steroid hormones by human cytochromes P450.
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
Role of polymorphic human cytochrome p450 enzymes in estrone oxidation.
Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer.
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.
The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China.
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
The Influence of CYP3A4 Polymorphism in Sex Steroids as a Risk Factor for Breast Cancer.
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells.
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
[Advances in the research of pharmacogenomics of tamoxifen].
[Genetic polymorphism and variability of steroid hormone metabolism: connection with risk of developing breast neoplasms]
Carcinogenesis
Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis.
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Expression and localization of CYP3A4 and CYP3A5 in human lung.
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells.
The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe?
The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
Carcinoma
Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells.
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Cytochrome P450 expression in oesophageal cancer.
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Dual-color fluorescence imaging to monitor CYP3A4 and CYP3A7 expression in human hepatic carcinoma HepG2 and HepaRG cells.
Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180.
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Expression alterations of cytochromes P4501A1, 2E1, and 3A, and their receptors AhR and PXR caused by 1-octyl-3-methylimidazolium chloride in mouse mammary carcinoma cells.
Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.
Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells.
Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.
Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells.
Inhibitory effect of nitric oxide on the induction of cytochrome P450 3A4 mRNA by 1,25-dihydroxyvitamin D3 in Caco-2 cells.
Interaction between Alcohol Consumption and CYP 2C19 Gene Polymorphism in Relation to Oesophageal Squamous Cell Carcinoma.
Interaction between CYP 2C19*3 polymorphism and smoking in relation to laryngeal carcinoma in the Chinese Han population.
Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene.
Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells.
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.
Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells.
Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Carcinoma, Ductal
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Carcinoma, Hepatocellular
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system.
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides.
Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.
Alisol B 23-acetate from the rhizomes of Alisma orientale is a natural agonist of the human pregnane X receptor.
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Biotransformation of 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-1-propynyl-estra-4,9-dien-3-one (RU486) in rat hepatoma variants.
Cis-Nerolidol Induces Endoplasmic Reticulum Stress and Cell Death in Human Hepatocellular Carcinoma Cells through Extensive CYP2C19 and CYP1A2 Oxidation.
Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A37).
Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: Implications for toxicity testing paradigms.
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells.
CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver.
CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells.
CYP450 enzyme-specific enantioselective species-specific response for metalaxyl in in vitro hepatic cells.
Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A.
Cytotoxic effects of benzbromarone and its 1'-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates.
Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.
Development of a Highly Sensitive Cytotoxicity Assay System for CYP3A4-Mediated Metabolic Activation.
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression.
Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.
Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.
Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro.
Fucoxanthin Attenuates Rifampin-Induced Cytochrome P450 3A4 (CYP3A4) and Multiple Drug Resistance 1 (MDR1) Gene Expression Through Pregnane X Receptor (PXR)-Mediated Pathways in Human Hepatoma HepG2 and Colon Adenocarcinoma LS174T Cells.
Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Histone deacetylase inhibitor stimulate CYP3A4 proximal promoter activity in HepG2 cells.
Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies.
Human liver oxidative metabolism of O6-benzylguanine.
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.
Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression.
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
Increased expression of drug-metabolizing enzymes in human hepatocarcinoma FLC-4 cells cultured on micro-space cell culture plates.
Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation.
Interactions of pharmaceuticals and other xenobiotics on hepatic pregnane X receptor and cytochrome P450 3A signaling pathway in rainbow trout (Oncorhynchus mykiss).
Metabolic Susceptibility of 2-Chlorothioxanthone and Its Toxic Effects on mRNA and Protein Expression and Activities of Human CYP1A2 and CYP3A4 Enzymes.
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells.
Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity.
Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research.
Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation.
Overexpression of CYP3A4, but not CYP2D6, promotes hypoxic response and cell growth of Hep3B cells.
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma; distinctive PK profiles from other solid tumors.
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Pungent ginger components modulates human cytochrome P450 enzymes in vitro.
Regulation of CYP2C19 expression by estrogen receptor {alpha}: implications for estrogen-dependent inhibition of drug metabolism.
Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells.
Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells.
Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway.
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide.
Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes.
Selective induction of the CYP3A family by endosulfan and DNA-adduct formation in different hepatic and hepatoma cells.
Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells.
Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: A study in human keratinocytes and human hepatoma cells.
Technical pentabromodiphenyl ether and hexabromocyclododecane as activators of the pregnane-X-receptor (PXR).
The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.
The effect of interferon-? on the expression of cytochrome P450 3A4 in human hepatoma cells.
The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma.
The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression.
Up-regulating CYP3A4 expression in C3A cells by transfection with a novel chimeric regulator of hPXR-p53-AD.
Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors.
Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.
Carcinoma, Non-Small-Cell Lung
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Carcinoma, Renal Cell
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Cytochrome P450 CYP3A in human renal cell cancer.
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Carcinoma, Squamous Cell
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
Interaction between Alcohol Consumption and CYP 2C19 Gene Polymorphism in Relation to Oesophageal Squamous Cell Carcinoma.
Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.
Cardiomyopathies
Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Cardiotoxicity
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Pharmaceutical Characterization of MyoNovin, a Novel Skeletal Muscle Regenerator: in silico, in vitro and in vivo Studies.
The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins.
Cardiovascular Diseases
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.
Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
Pantoprazole does not interact with nifedipine in man under steady-state conditions.
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Celiac Disease
Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism.
Theoretical pharmacokinetic drug alterations in pediatric celiac disease.
Cerebral Hemorrhage
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
Cerebral Infarction
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
[Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].
Cerebrovascular Disorders
Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease.
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.
Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Reduced Clopidogrel Metabolism in a Multiethnic Population: Prevalence and Rates of Recurrent Cerebrovascular Events.
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
Chemical and Drug Induced Liver Injury
Lack of association between genetic polymorphisms of CYP3A4, CYP2C9, CYP2C19 and anti-tuberculosis drug-induced liver injury in community-based Chinese population.
Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity.
Cholangiocarcinoma
Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450.
Cholestasis
Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice.
Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Ligand diversity of human and chimpanzee CYP3A4: Activation of human CYP3A4 by lithocholic acid results from positive selection.
Novel pathways of bile acid metabolism involving CYP3A4.
Optimization of the HepaRG cell model for drug metabolism and toxicity studies.
Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis.
Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: a possible mechanism for its hepatoprotective property against lithocholic acid-induced injury.
Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.
Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.
Cholestasis, Intrahepatic
[Association between polymorphisms of CYP17 and CYP3A4 genes and intrahepatic cholestasis of pregnancy in Chengdu]
Cocarcinogenesis
Biomarkers of effect in evaluating dithianon cocarcinogenesis: selective induction and suppression of murine CYP3A isoform.
Coinfection
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Colitis
Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis.
Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations.
Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.
Colitis, Ulcerative
Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.
Colonic Neoplasms
19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro.
Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells.
Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention.
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.
Lithocholic acid can carry out in vivo functions of vitamin D.
Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro.
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Colorectal Neoplasms
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Genetic Variations in the Xenobiotic-Metabolizing Enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and Susceptibility to Colorectal Cancer Among Turkish People.
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Conjunctivitis, Allergic
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Connective Tissue Diseases
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
Coronary Artery Disease
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease.
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Can prasugrel decrease the extent of periprocedural myocardial injury during elective PCI?
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects.
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease.
Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Enhanced active metabolite generation and platelet inhibitionwith prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Genetic determinants of platelet response to clopidogrel.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Coronary Disease
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
Positive Clinical Response to Clopidogrel is Independent of Paraoxonase 1 Q192R and CYP2C19 Genetic Variants.
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project.
[Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Craniocerebral Trauma
Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat.
Crohn Disease
CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Cryptorchidism
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Cushing Syndrome
Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy.
Fluticasone furoate induced iatrogenic Cushing syndrome in a pediatric patient receiving anti-retroviral therapy.
Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature.
Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test.
Cystic Fibrosis
Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor.
Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis.
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis.
Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis.
Death, Sudden, Cardiac
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Dehydration
Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs.
Delirium
Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction.
Extreme Duration of Diazepam-Associated Sedation in a Patient With Alcohol Delirium and CYP2C19 Polymorphisms.
Dermatitis
Trichloroethylene-induced hypersensitivity dermatitis was associated with hepatic metabolic enzyme genes and immune-related genes.
Dermatitis, Atopic
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
Diabetes Mellitus
Antiplatelet resistance in outpatients with monitored adherence.
Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus.
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
[Variable extent of platelet responsiveness to clopidogrel inhibition: "clopidogrel resistance"?]
Diabetes Mellitus, Type 2
Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.
Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
The pharmacokinetics of pioglitazone in Thai healthy subjects.
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
Diabetic Retinopathy
Sex differences in the effect of cytochrome P450 2C19 polymorphisms on the risk of diabetic retinopathy: a retrospective longitudinal study in Japanese patients with type 2 diabetes.
Digestive System Neoplasms
Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.
Drug Resistant Epilepsy
Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Drug-Related Side Effects and Adverse Reactions
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin.
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Clinical relevance of pharmacogenetics.
Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients.
Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.
CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs.
CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.
Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico.
Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology.
Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker.
Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.
Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms.
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China.
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors.
Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins.
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype.
[Cytochrome P-450 3A4--the most important arena for drug interactions in the body]
[Genotrping of CYP2D6 and CYP2C19]
Duodenal Ulcer
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China.
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Dyslipidemias
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity.
Potential interaction between troglitazone and atorvastatin.
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin.
Endocrine System Diseases
Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes.
Endometrial Neoplasms
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.
Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells.
Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion.
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Endometriosis
Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis.
CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis.
CYP2C19 polymorphism increases the risk of endometriosis.
High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19.
Is cytochrome P450 3A4 regulated by menstrual cycle hormones in control endometrium and endometriosis?
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Role of CYP2C19 polymorphisms in patients with endometriosis.
Role of cytochrome P450 2C19 polymorphisms and body mass index in endometriosis: A case-control study.
TGF-? Induces Endometriotic Progression via a Noncanonical, KLF11-Mediated Mechanism.
[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study].
Endophthalmitis
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Endotoxemia
Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target genes CYP3A.
Eosinophilia
Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis.
Epilepsies, Myoclonic
Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome.
Epilepsy
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy.
Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment.
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.
Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction.
Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy.
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children.
The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]
[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Epilepsy, Frontal Lobe
Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment.
Erectile Dysfunction
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Esophageal Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Esophageal Squamous Cell Carcinoma
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.
Esophagitis
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Esophagitis, Peptic
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
CYP2C19 Genotypes Determine the Efficacy of On-demand Therapy of Pantoprazole for Reflux Esophagitis as Los-Angeles Grade C & D.
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
Essential Hypertension
Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients.
Essential Tremor
CYP2C19 Polymorphism and Risk for Essential Tremor.
Exanthema
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.
Familial Mediterranean Fever
Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever.
Fatty Liver
Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1'-Hydroxylation.
[Obesity and steatohepatitis. Histologic aspects]
Fatty Liver, Alcoholic
A new approach to drug therapy in non-alcoholic steatohepatitis (NASH).
Febrile Neutropenia
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Foot Ulcer
Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
Gastritis
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Gastroesophageal Reflux
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux.
Characteristics of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms -Is Switching Proton Pump Inhibitors Based on the Patient's CYP2C19 Genotype an Effective Management Strategy?
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastr?c pH in extensive metabolizer patients with gastroesophageal reflux disease.
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
CYP2C19 polymorphism and proton pump inhibitors.
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19.
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Pharmacogenetics of the proton pump inhibitors: a systematic review.
Pharmacogenomics of proton pump inhibitors.
Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Putting Out the Fire: The Relationship of Pharmacogenetics and Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease.
Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-(13)C breath test in GERD patients: clinical relevance for personalized medicine.
[Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors]
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
[Test of refractory gastroesophageal reflux disease]
Gastrointestinal Diseases
Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.
Gastrointestinal Neoplasms
High CYP2C19 phenotypic variability in gastrointestinal cancer patients.
Gastrointestinal Stromal Tumors
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Gingival Hyperplasia
Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Glioblastoma
Gefitinib Accumulation in Glioblastoma Tissue.
MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.
Gliosarcoma
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Glycogen Storage Disease
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Graft vs Host Disease
A novel drug interaction between busulfan and blinatumomab.
Gynecomastia
Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17.
Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
Heart Diseases
Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
[Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
[Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case]
Heart Failure
CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.
Dronedarone: current evidence and future questions.
Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias.
Hemangioma
Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.
Hematologic Neoplasms
CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma.
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Hepatic Insufficiency
Altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms.
Differential Effect of Liver Cirrhosis on the Pregnane X Receptor-Mediated Induction of CYP3A1 and 3A2 in the Rat.
Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
Hepatitis
Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis.
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Hepatitis B
Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation.
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Single-nucleotide polymorphism genotyping using a novel multiplexed electrochemical biosensor with nonfouling surface.
Hepatitis B, Chronic
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
Hepatitis C
Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors.
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.
The importance of drug-drug interactions in the DAA era.
The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir.
Hepatitis C, Chronic
Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
Hepatitis, Chronic
Genotype analysis of the CYP2C19 gene in the Japanese population.
In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Hepatoblastoma
Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7.
Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene.
Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells.
Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4.
Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters.
Hepatomegaly
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor.
Quantitative structure-activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis.
Herpes Zoster
Molecular Analysis of Endocrine Disruption in Hornyhead Turbot at Wastewater Outfalls in Southern California Using a Second Generation Multi-Species Microarray.
HIV Infections
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.
Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition.
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.
Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug.
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
[Implications of antiretroviral therapy in oral medicine--a review of literature]
HIV Seropositivity
MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease.
Hodgkin Disease
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis.
Hypercholesterolemia
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.
Comparison of endothelial function in the carotid artery between normal and short-term hypercholesterolemic rabbits.
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin.
Hyperglycemia
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.
Hyperglycinemia, Nonketotic
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Hyperkalemia
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Hyperparathyroidism
Effects of Chronic Renal Failure on Brain Cytochrome P450 in Rats.
Hypersensitivity
Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors.
Correlation analysis of gene polymorphisms and ?-lactam allergy.
Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s)
Trichloroethylene-induced hypersensitivity dermatitis was associated with hepatic metabolic enzyme genes and immune-related genes.
Hypertension
Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.
Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population.
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Augmented arterial pressure responses to cyclosporine in spontaneously hypertensive rats. Role of cytochrome P-450 3A.
Bimodal distribution of renal cytochrome P450 3A activity in humans.
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket.
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
CYP2C19 genotype is an independent predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel Post Percutaneous Coronary Intervention.
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
CYP3A5 polymorphism, amlodipine and hypertension.
Effect of benidipine on simvastatin metabolism in human liver microsomes.
Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro.
Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.
Gender Differences in the Impact of CYP2C19 Polymorphisms and Low-Grade Inflammation on Coronary Microvascular Disorder.
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Intravenous diltiazem and CYP3A-mediated metabolism.
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Sequence diversity and haplotype structure at the human CYP3A cluster.
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
[Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case]
Hypertension, Pulmonary
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Hypertriglyceridemia
Prediction of genetic risk for dyslipidemia.
Hypoalbuminemia
Theoretical pharmacokinetic drug alterations in pediatric celiac disease.
Hypoglycemia
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Hypokalemia
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Hypospadias
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Hypotension
Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.
Flibanserin: From Bench to Bedside.
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Immune Reconstitution Inflammatory Syndrome
How best to approach endocrine evaluation in patients with HIV in the era of combined antiretroviral therapy?
Infection
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice.
Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.
An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells.
Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines.
Differences in the Serum 4?-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Downregulation of Hepatic Cytochrome P450 3A in Mice Infected with Babesia microti.
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.
Effect of bacterial and host factors on Helicobacter pylori eradication therapy.
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha.
Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.
Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial.
Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach.
Gene expression profiling of porcine mammary epithelial cells after challenge with Escherichia coli and Staphylococcus aureus in vitro.
Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma.
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation.
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A.
Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.
Lower expression of HNF4? and PGC1? might impair rifampicin-mediated CYP3A4 induction under conditions where PXR overexpressed in human fetal liver cells.
Metabolism of Diazepam and Ethosuximide in rats with malaria and endotoxin-induced fever.
Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients.
Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection of the brain.
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea.
Personalized medicine for eradication of Helicobacter pylori.
Pharmacogenetics of the proton pump inhibitors: a systematic review.
Pharmacogenomics of proton pump inhibitors.
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report.
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration.
Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
[Effect of CYP2C19 gene polymorphism on eradication treatment efficacy of Helicobacter pylori infection]
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]
[Effects of chronic HBV infection on human hepatic cytochrome P450 3A4]
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism]
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
[Polymorphism of cytochrome P-450 gene in the light of Helicobacter pylori eradication efficiency]
[Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism]
Infertility
Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertility.
Inflammatory Bowel Diseases
Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor.
Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.
Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Influenza, Human
Effect of age and degree of immune activation on cytochrome P450 3A4 activity after influenza immunization.
Effect of influenza immunization on CYP3A4 activity in vivo.
Effect of influenza immunization on CYP3A4 activity.
Insulin Resistance
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.
Intestinal Diseases
Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism.
Intracranial Aneurysm
Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.
Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling.
Invasive Fungal Infections
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.
Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
[The polymorphism of cytochrome P(450) 2C19 gene in patients with invasive fungal infections.]
Ischemic Attack, Transient
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Ketosis
High fat diet induced obesity is mitigated in Cyp3a-null female mice.
Kidney Diseases
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Kidney Failure, Chronic
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.
Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease.
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Significant increase in plasma 4?-hydroxycholesterol concentration in patients after kidney transplantation.
Kidney Neoplasms
Cytochrome P450 CYP3A in human renal cell cancer.
Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
Leishmaniasis, Visceral
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.
Leprosy
Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.
Leukemia
Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL.
Association of CYP3A4 genotype with treatment-related leukemia.
Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Etoposide quinone is a redox-dependent topoisomerase II poison.
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia.
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs.
The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.
[The relationship between cytochrome P450, subfamily IIIA, polypeptide 5 gene and drug resistance in leukemia cell lines]
Leukemia, Erythroblastic, Acute
Changes in the expression of cytochrome P450 genes in hemin-induced differentiated K562 cells.
Oxidative stress induces GSTP1 and CYP3A4 expression in the human erythroleukemia cell line, K562.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia.
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib-a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
Leukemia, Myeloid, Acute
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.
Budget Impact Analysis of CYP2C19 Genotyping to Target Voriconazole Prophylaxis During Induction-Consolidation Therapy in Acute Myeloid Leukemia (AML) in The United States.
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Leukopenia
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Lipodystrophy
How best to approach endocrine evaluation in patients with HIV in the era of combined antiretroviral therapy?
Liver Cirrhosis
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores.
CYP3A4*18 polymorphisms and anti-hepatitis A virus seroprevalence.
Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.
Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Effects of zedoary turmeric oil on P450 activities in rats with liver cirrhosis induced by thioacetamide.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Reduced urinary 6beta-hydroxycortisol to cortisol ratios in patients with liver cirrhosis.
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
[Effect of Fuzheng Huayu recipe on CYP450 isozymes in normal and liver fibrosis rats].
[Obesity and steatohepatitis. Histologic aspects]
[Study on CYP1A2, CYP2C9/10 and CYP2C19 activities in rats to create liver cirrhosis by using multi-factor complex].
Liver Cirrhosis, Alcoholic
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.
Liver Cirrhosis, Biliary
Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Liver Diseases
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics.
Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores.
CYP3A4*18 polymorphisms and anti-hepatitis A virus seroprevalence.
Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Influence of clinicopathological variables on CYP protein expression in human liver.
Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations.
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases.
Rapid Onset of Iatrogenic Adrenal Insufficiency in a Patient with Cystic Fibrosis-Related Liver Disease Treated with Inhaled Corticosteroids and a Moderate CYP3A4 Inhibitor.
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1'-Hydroxylation.
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Liver Diseases, Alcoholic
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system.
Liver Failure
Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance.
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder.
Liver Failure, Acute
In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Liver Neoplasms
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Long QT Syndrome
Review article: cardiac adverse effects of gastrointestinal prokinetics.
Lung Diseases, Interstitial
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Lung Neoplasms
Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.
Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population.
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
The Rationale for Repurposing Sildenafil as an Adjuvant to Lung Cancer Treatment.
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Lupus Erythematosus, Systemic
CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Cytochrome P450 Polymorphism as a Predictor of Ovarian Toxicity to Pulse Cyclophosphamide in Systemic Lupus Erythematosus.
Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.
Lupus Nephritis
Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Lymphoma
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis.
Lymphoma, B-Cell
Development of an alternative zebrafish model for drug-induced intestinal toxicity.
Lymphoma, Mantle-Cell
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Lymphoma, Non-Hodgkin
Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
[Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]
Lymphoma, T-Cell
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Macular Degeneration
Associations between Rs4244285 and Rs762551 gene polymorphisms and age-related macular degeneration.
Malaria
Analysis of Sepik populations of Papua New Guinea suggests an increase of CYP2C19 null allele frequencies during the colonization of Melanesia.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls.
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers.
Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.
Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers.
Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450.
Metabolism of Diazepam and Ethosuximide in rats with malaria and endotoxin-induced fever.
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines.
Malaria, Falciparum
Analysis of Sepik populations of Papua New Guinea suggests an increase of CYP2C19 null allele frequencies during the colonization of Melanesia.
Malnutrition
Effect of protein and calorie malnutrition on drug metabolism in rat - in vitro.
medium-chain acyl-coa dehydrogenase deficiency
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Medulloblastoma
Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia?inducible factor 1??mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation.
P450-expression in brain tumors.
Melanoma
Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.
Melanosis
Histopathology of melanosis coli and determination of its associated genes by comparative analysis of expression microarrays.
Metabolic Syndrome
Age-dependent features of CYP3A, CYP2C, and CYP2E1 functioning at metabolic syndrome.
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people.
Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal.
Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Metrorrhagia
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Microvascular Angina
Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.
CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina.
Migraine Disorders
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
Miosis
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.
Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil.
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P-Glycoprotein Activities.
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Movement Disorders
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
Multiple Myeloma
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.
[Antiangiogenic Activity of Thalidomide In Vitro Mediated by Cytochrome CYP2C19.]
[Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma]
Multiple Sclerosis
Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Muscular Diseases
A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
Clinical implications of pharmacogenetic variation on the effects of statins.
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage.
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
The influence of high-dose simvastatin and diltiazem on myocardium in rabbits: a haemodynamic study.
The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study.
The role of mitochondria in statin-induced myopathy.
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.
Mycoses
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
Pharmacokinetics of Cyclosporine a Conversion from Twice-Daily Infusion to Oral Administration in Allogeneic Hematopoietic Stem Cell Transplantation.
Myelodysplastic Syndromes
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.
Myocardial Infarction
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Association of CYP2C19 Genotype With Periprocedural Myocardial Infarction After Uneventful Stent Implantation in Chinese Patients Receiving Clopidogrel Pretreatment.
Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
CYP2C19 genotype is an independent predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel Post Percutaneous Coronary Intervention.
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina.
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Genetic determinants of response to clopidogrel and cardiovascular events.
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.
Implementation of a pharmacogenetic management service for postmyocardial infarction care in a community pharmacy.
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Pharmacogenomics of antiplatelet drugs.
Pharmacogenomics of clopidogrel: Evidence and perspectives.
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Predicting clopidogrel response using DNA samples linked to an electronic health record.
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre tri.
Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction?- The CALDERA-GENE Study.
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
[Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
Myocardial Ischemia
Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
Myoclonus
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Nasopharyngeal Carcinoma
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Nasopharyngeal Neoplasms
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Neoplasm Metastasis
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase.
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin((R))) in cancer subjects.
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Neoplasms
4?-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes.
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors.
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
Association of CYP3A variants with kidney transplant outcomes.
Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL.
Association of CYP3A4 genotype with treatment-related leukemia.
Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.
Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.
Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Carcinogenicity of cyproterone acetate in the mouse.
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Cyclamen Trochopteranthum: Cytotoxic activity and possible adverse interactions including drugs and carcinogens.
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.
CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.
CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases.
CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis.
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells.
CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy.
CYP3A4: a potential prostate cancer risk factor for high-risk groups.
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Cytochrome P450 3A and their regulation.
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Cytochrome P450 CYP3A in human renal cell cancer.
Cytochrome P450 expression in oesophageal cancer.
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
Cytotoxicity and cytochrome P450 inhibitory activities of Clinacanthus nutans.
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
Development of a novel, fully-automated genotyping system: principle and applications.
Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents.
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
Development of an alternative zebrafish model for drug-induced intestinal toxicity.
Dietary modulation of the biotransformation and genotoxicity of aflatoxin B(1).
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture.
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.
Differential expression of cytochrome p450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma.
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.
Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells.
Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma.
Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats.
Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
Effect of Botanical Immunomodulators on Human CYP3A4 Inhibition: Implications for Concurrent Use as Adjuvants in Cancer Therapy.
Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients.
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.
Effects of Oral Anorexiant Sibutramine on the Expression of Cytochromes P450s in Human Hepatocytes and Cancer Cell Lines.
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Effects of ready to drink teas on AhR- and PXR-mediated expression of cytochromes P450 CYP1A1 and CYP3A4 in human cancer cell lines and primary human hepatocytes
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Enantioselective metabolism and cytotoxicity of R-Ifosfamide and S-Ifosfamide by tumor cell-expressed cytochromes P450.
Enhanced expression of cytochrome P450 in stomach cancer.
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma.
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.
Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1-and 4-aminobiphenyl-DNA adducts.
Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer.
Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Expression of cytochromes P450 in human breast tissue and tumors.
Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Factors affecting cytochrome P-450 3A activity in cancer patients.
Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial.
Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3.
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.
Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation.
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Genetics of the variable expression of CYP3A in humans.
Genotype relationships in the CYP3A locus in Caucasians.
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Identification of NR1I2 genetic variation using resequencing.
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Impact of hepatic malignancy on CYP3A4 gene expression.
In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer.
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450.
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.
In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients.
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
Increased transcriptional activity of the CYP3A4*1B promoter variant.
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.
Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2.
Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice.
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.
Inoculation of human tumor cells alters the basal expression but not the inducibility of Cyp enzymes in tumor-bearing mouse liver.
Interaction of N-(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates with Human Liver Microsomal Cytochromes P450: Comparison with Free Doxorubicin.
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.
Medication use in breast cancer survivors compared to midlife women.
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.
Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells.
Modulation of irinotecan metabolism by ketoconazole.
Modulation of multidrug resistance in cancer cells by chelidonine and Chelidonium majus alkaloids.
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Novel Tetrazole-containing Analogs of Itraconazole as Potent Anti-angiogenic Agents with Reduced CYP3A4 Inhibition.
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis.
Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data.
Optimizing the erythromycin breath test for use in cancer patients.
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Overexpression of CYP3A4, but not CYP2D6, promotes hypoxic response and cell growth of Hep3B cells.
P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
P450-expression in brain tumors.
Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma; distinctive PK profiles from other solid tumors.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Polymorphism of CYP450 and cancer susceptibility.
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Poor Metabolizers at the Cytochrome P450 2C19 Loci Is at Increased Risk of Developing Cancer in Asian Populations.
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Population Pharmacokinetics of Phenytoin Based on NONMEN in Patients with Intracranial Tumor during the First Week of Post-craniotomy.
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia.
Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.
Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk.
Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Reactivation of tuberculosis during temsirolimus therapy.
Regulation of drug resistance by human pregnane X receptor in breast cancer.
Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes.
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents.
Sequence diversity and haplotype structure at the human CYP3A cluster.
Significant transcriptional down-regulation of the human MDR1 gene by beta-naphthoflavone: a proposed hypothesis linking potent CYP gene induction to MDR1 inhibition.
Simvastatin-fluconazole causing rhabdomyolysis.
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs.
The anticancer effects and mechanisms of fucoxanthin combined with other drugs.
The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers.
The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue.
The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer.
The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability.
The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.
The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma.
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Tumor necrosis factor alpha partially contributes to lipopolysaccharide-induced downregulation of CYP3A in fetal liver: Its repression by a low dose LPS pretreatment.
Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Tumour cytochrome P450 and drug activation.
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
Universal tumor antigens as targets for immunotherapy.
Valspodar: current status and perspectives.
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
[Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]
[Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor].
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Nephritis, Interstitial
Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype.
Nephrosis
Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Nephrotic Syndrome
Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons.
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Nervous System Diseases
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Neuralgia
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C).
Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
Neuroblastoma
Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.
Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation.
Neutropenia
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Non-alcoholic Fatty Liver Disease
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice.
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.
Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease.
Obesity
Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
Clinical pharmacokinetics and pharmacodynamics of clopidogrel.
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.
Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
Identifying clinically-relevant sources of variability: the clopidogrel challenge.
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.
Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
Onychomycosis
Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis.
Osteomalacia
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia.
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia.
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.
Osteonecrosis
Correlation Between Steroid-Induced Osteonecrosis of The Femoral Head and Hepatic CYP3A Activity: A Systematic Review and Meta-Analysis.
Genetic polymorphisms of CYP3A4 among Chinese patients with steroid-induced osteonecrosis of the femoral head.
Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model.
Low levels of steroid-metabolizing hepatic enzyme (cytochrome P450 3A) activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose.
[Hepatic CYP3A activity in association with development of osteonecrosis of the femoral head]
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Osteoporosis
A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.
Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis.
The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density.
Osteosarcoma
Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma.
Ovarian Neoplasms
Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.
Polymorphisms of
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
Pancreatic Neoplasms
Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in pancreatic cancer patients.
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib--an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer.
Pancreatitis
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Parkinson Disease
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Genotype analysis of the CYP2C19 gene in the Japanese population.
Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
Peptic Ulcer
Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam.
Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.
EFFECT OF CYP2C19 GENETIC POLYMORPHISMS ON THE EFFICACY OF PROTON PUMP INHIBITOR-BASED TRIPLE ERADICATION THERAPY IN SLAVIC PATIENTS WITH PEPTIC ULCERS: A META-ANALYSIS.
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
Fluoxetine inhibition of CYP3A4 potentiating adrenal suppression and peptic ulcer disease from intra-articular triamcinolone injections.
Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.
Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients.
[HIGH FREQUENCY OF CYP2C19 ULTRARAPID METABOLIZERS IN RUSSIAN PATIENTS WITH PEPTIC ULCER].
[THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS].
Pericardial Effusion
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Peripheral Arterial Disease
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Peripheral Nervous System Diseases
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.
Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole.
Porphyrias
Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men.
Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.
The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Premature Birth
The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Prostatic Hyperplasia
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Prostatic Neoplasms
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Androgens and the molecular epidemiology of prostate cancer.
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.
Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
Clinical implications of CYP3A polymorphisms.
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer.
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.
CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
CYP3A4: a potential prostate cancer risk factor for high-risk groups.
Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Prevalent mutations in prostate cancer.
Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor.
Review of studies on metabolic genes and cancer in populations of African descent.
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
Variant in sex hormone-binding globulin gene and the risk of prostate cancer.
Vitamin D in Prostate Cancer.
[Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Pruritus
An update on the physiopathology and therapeutic management of cholestatic pruritus in children.
Psoriasis
Allelic variants of drug metabolizing enzymes as risk factors in psoriasis.
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Puberty, Precocious
Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls.
Pulmonary Disease, Chronic Obstructive
Expression of cytochrome P450 mRNAs in Type II alveolar cells from subjects with chronic obstructive pulmonary disease.
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
quinine 3-monooxygenase deficiency
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate.
Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Renal Insufficiency
Association of plasma concentration of 4?-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
Significant increase in plasma 4?-hydroxycholesterol concentration in patients after kidney transplantation.
Simvastatin: present and future perspectives.
The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.
The pharmacokinetics of paliperidone versus risperidone.
[Pharmacokinetics, interactions and mechanism of action of maraviroc]
Renal Insufficiency, Chronic
Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation.
Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.
Down-regulation of hepatic CYP3A in chronic renal insufficiency.
Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Reperfusion Injury
Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Respiratory Insufficiency
Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression.
Rhabdomyolysis
Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena.
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient.
Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib.
Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications.
Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review.
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration.
Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx?
[Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone].
[The incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan]
Rheumatic Diseases
Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Rhinitis, Allergic
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rickets
CYP3A4 mutation causes vitamin D-dependent rickets type 3.
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Sarcoma
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.
Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives.
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Sarcoma, Avian
Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver.
Sarcoma, Ewing
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
Sarcoma, Experimental
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Schistosomiasis
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
Schistosomiasis mansoni
Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.
Seizures
Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-?B activity in the bEnd.3 cells.
Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures.
Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures.
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Sepsis
Catecholamines induce an inflammatory response in human hepatocytes.
Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.
Severe Combined Immunodeficiency
Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
Shock, Septic
Catecholamines induce an inflammatory response in human hepatocytes.
Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide.
Sleep Initiation and Maintenance Disorders
Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.
Small Cell Lung Carcinoma
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.
ST Elevation Myocardial Infarction
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Correction to: Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.
Starvation
Expression and distribution of cytochrome P450 enzymes in male rat kidney: effects of ethanol, acetone and dietary conditions.
Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways.
[Effect of starvation and acetone on the enzyme systems of biotransformation and toxicity of xenobiotics--CYP2E1 substrates in rats]
steroid 21-monooxygenase deficiency
Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.
Stevens-Johnson Syndrome
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Stomach Neoplasms
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
Enhanced expression of cytochrome P450 in stomach cancer.
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
[Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor].
Stomach Ulcer
A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
Stroke
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.
Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping.
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
Pharmacogenomics of antiplatelet drugs.
Polymorphisms of cytochrome P450 are potential candidates that could potentially help clinicians on the treatment of cardiovascular diseases among Asian populations.
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
The effect of the CYP 2C19*2 polymorphism on stroke care.
The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Subarachnoid Hemorrhage
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
Syncope
Flibanserin: From Bench to Bedside.
Tachycardia, Ventricular
A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study.
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Tardive Dyskinesia
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
Thalassemia
Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.
Thrombocytopenia
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Thrombosis
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.
Clopidogrel "resistance": pre- vs post-receptor determinants.
Clopidogrel resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis.
Cytochrome p-450 polymorphisms and response to clopidogrel.
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Do
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Epidemiology of CYP3A4-mediated Clopidogrel Drug-Drug Interactions and Their Clinical Consequences.
Evaluation of the effect of SNPs in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose.
Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Integrative medicine on optimizing clopidogrel and aspirin therapy.
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Pharmacogenomics of antiplatelet drugs.
Pharmacogenomics of clopidogrel: Evidence and perspectives.
Pharmacogenomics of oral antiplatelet drugs.
Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Prediction of Clopidogrel Low Responders by a Rapid CYP2C19 Activity Test.
Prevalence of CYP2C19 polymorphisms in the Lebanese population.
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3).
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.
[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Torsades de Pointes
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
High dose methadone and ventricular arrhythmias: a report of three cases.
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Torsade de pointes induced by cisapride/clarithromycin interaction.
Toxoplasmosis, Cerebral
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Triple Negative Breast Neoplasms
Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer.
Tuberculosis
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Biofragments: An Approach towards Predicting Protein Function Using Biologically Related Fragments and its Application to Mycobacterium tuberculosis CYP126.
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
CYP3A genotypes in Bangladeshi tuberculosis patients.
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis.
Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.
Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.
Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.
Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption.
Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV.
[Tuberculosis associated with the human immunodeficiency virus]
Tuberculosis, Multidrug-Resistant
Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.
Uremia
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Hemodialysis acutely improves hepatic CYP3A4 metabolic activity.
Recovery of CYP3A Phenotype Following Kidney Transplantation.
Urinary Bladder Neoplasms
Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects.
Urinary Incontinence
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.
Vaccinia
Human liver oxidative metabolism of O6-benzylguanine.
Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism.
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.
Vascular Diseases
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Vasculitis
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Venous Thrombosis
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis.
Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk.
Virus Diseases
Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A.
Vision Disorders
Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.
Vitamin D Deficiency
CYP3A4 mutation causes vitamin D-dependent rickets type 3.
Interplay between Vitamin D and the Drug Metabolizing Enzyme CYP3A4.
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Vitamin D pathway gene polymorphisms influenced vitamin D level among pregnant women.
Xanthomatosis, Cerebrotendinous
Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor.
Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis.